pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly and
Eli Lilly Co.
Eli Lilly and clinical programs — 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Founded
- 1876
- Employees
- 55,860
- Programs
- 107
- Drugs
- 99
- Patents
- 0
Eli Lilly and projects
25 ClinicalTrials.gov programs sponsored by Eli Lilly and.
Eli Lilly and has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A Phase 1 Study on the effects of LY3410738 (...
Eli Lilly Co.
Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
1 trial -
A Study of LY3200882 in Participants With Solid Tumors.
Eli Lilly Co.
Metastatic cancer, Solid Tumor
1 trial -
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly Co.
Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor
1 trial -
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.
Eli Lilly Co.
Cancer
1 trial -
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly Co.
Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis
1 trial -
EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers
Eli Lilly Co.
Breast Cancer, Endometrial cancer
1 trial -
I3Y-MC-JPCE
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial -
I3Y-MC-JPEI
Eli Lilly Co.
Prostatic Neoplasms
1 trial -
I8H-MC-BDDG
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
J1I-MC-GZQF
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
J1I-MC-GZQG
Eli Lilly Co.
Diabetes Mellitus
1 trial -
J2S-MC-GZML
Eli Lilly Co.
Healthy, Hepatic Insufficiency
1 trial -
J3L-MC-EZEH
Eli Lilly Co.
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
1 trial -
J3R-MC-YDAH
Eli Lilly Co.
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
1 trial -
J4P-MC-IYAB
Eli Lilly Co.
Type 1 Diabetes Mellitus
1 trial -
J5J-OX-JZZA
Eli Lilly Co.
KRAS G12D-mutant solid tumors.
1 trial -
J5Q-OX-JRDA
Eli Lilly Co.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.
1 trial -
J6B-MC-YKAA
Eli Lilly Co.
Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2
1 trial -
J6I-MC-OWAA
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
JIO-MC-JZHD
Eli Lilly Co.
Neuroblastoma
1 trial -
LOXO-ENC-23001
Eli Lilly Co.
Advanced/metastatic solid tumor
1 trial -
LOXO-FRA-24001
Eli Lilly Co.
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
1 trial -
LOXO-IDH-20001
Eli Lilly Co.
Advanced Hematologic Malignancies
1 trial -
LOXO-LNC-24001
Eli Lilly Co.
Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
1 trial -
LOXO-PIK-21001
Eli Lilly Co.
Advanced Breast Cancer and Other Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does Eli Lilly and have?
25 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.